Case Study

系统建模在临床开发中显著提升效率并降低成本

Discover how an IO-focused company developing immunotherapies applied QSP modeling solutions for cost-effective clinical development.…

Certara2024 年 7 月 12 日

Press Coverage

加快激酶抑制剂在肿瘤学领域的应用进程

The potential of PBPK modeling in answering key questions around these drugs. Hannah Jones, PhDMasoud…

Certara2024 年 5 月 20 日

Blog

如何在 FDA 的监管下开发孤儿药

罕见病是公共卫生领域的优先事项。FDA has launched several programs and a final…

Certara2024 年 2 月 21 日

Publication

将实用性要素融入研究设计，优化肿瘤学随机临床试验

A FRIENDS OF CANCER RESEARCH WHITE PAPER The article explores the complex landscape of determining…

Certara2023 年 12 月 19 日

Poster

FDA 加速批准肿瘤适应症药物的趋势

The FDA has modified and increased expectations around data needed to support accelerated approvals in…

Certara2023 年 9 月 20 日

Poster

肿瘤药物早期临床试验中患者报告结局（PROs）的采用：挑战与机遇

Despite changes in regulatory expectations, adoption of PROs in early-phase oncology trials remains very low…

Certara2023 年 9 月 20 日

Conference

American College of Toxicology 2026 Annual Meeting

– – Booth

Kevin Snyder, PhD2023 年 5 月 24 日

Publication

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

Explore how tumor growth inhibition modeling can support go/no-go decisions in early Phase Ib/II oncology…

Certara2023 年 3 月 24 日

Conference

Asembia AXS26 Summit

–

Certara2023 年 2 月 15 日

Conference

ISPOR International Annual Conference 2026

–

Certara2023 年 2 月 15 日

治疗领域

系统建模在临床开发中显著提升效率并降低成本

加快激酶抑制剂在肿瘤学领域的应用进程

如何在 FDA 的监管下开发孤儿药

将实用性要素融入研究设计，优化肿瘤学随机临床试验

FDA 加速批准肿瘤适应症药物的趋势

肿瘤药物早期临床试验中患者报告结局（PROs）的采用：挑战与机遇

American College of Toxicology 2026 Annual Meeting

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

Asembia AXS26 Summit

ISPOR International Annual Conference 2026

订阅时事通讯

快捷链接

解决方案

联系我们